Piloting the IPROACTIF Program to Preserve Functioning and Prevent Cognitive Decline
Heart Disease (Coronary Artery Disease, Ischemic Heart Disease, Hypertensive Heart Disease), Uncontrolled Diabetes (HBA1c ≥ 10)
About this trial
This is an interventional prevention trial for Heart Disease (Coronary Artery Disease, Ischemic Heart Disease, Hypertensive Heart Disease) focused on measuring chronic disease, aging, physical function, executive function, activities of daily living, primary care
Eligibility Criteria
Inclusion Criteria:
- English speaking
- Community-dwelling
- 55 years of age
- Primary diagnosis of heart disease (coronary artery disease, ischemic heart disease, hypertensive heart disease), or uncontrolled diabetes (HBA1c greater than/equal to 10)
- Self-reported risk of functional decline (score of 3 or higher) on the 11-item Brief Risk Identification of Geriatric Health Tool or self-reported need for assistance with disease management
Exclusion Criteria
- Current/past diagnosis of stroke or other neurological disorders
- Receiving pharmacological treatment for cognition
- Receiving outpatient rehabilitation services
- Participating in other exercise or ADL-focused intervention studies
- Non-English speaking
- Residing in a long-term care institution
- Compromised decision-making capacity (score >8 on SOMCT)
Sites / Locations
- University of Illinois at ChicagoRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
IPROACTIF
Usual care
12 weekly sessions. First two sessions focus on comprehensive assessment of physical and executive functioning, assessment of home safety and accessibility, assessment of ADL/IADL competence and performance in context; information in these areas is used by the interventionist to collaboratively identify three patient-centered goals. Goal planning is followed by 10 treatment sessions. Treatment sessions focus on chronic disease education, problem solving issues related to disease management by modifying daily routines, recommendations for embedding physical activity in everyday tasks, and environmental modifications or activity adaptations to increase ADL/IADL independence.
Participants in the control group will receive usual services which might include primary care and prescription medications for chronic disease management.